Debevoise Advises Leapfrog in the Sale of a 30% Stake in Goodlife to CFAO Healthcare

1 April 2022

Debevoise & Plimpton LLP is advising leading global impact investment group LeapFrog Investments in the sale of a 30% stake in Goodlife Pharmacies to Eurapharma (“CFAO Healthcare”). This transaction will be the first partial sale for the LeapFrog healthcare team, investing out of LeapFrog Emerging Consumer Fund III, which launched in 2017. For more information, please see LeapFrog’s press release.

LeapFrog invests in exceptional businesses in Africa and Asia, partnering with their leaders to achieve leaps of growth, profitability and impact. CFAO Healthcare is a leader in the African pharmaceutical market, handling distribution of pharmaceutical products and medicines in more than 23 countries in Africa. Goodlife Pharmacies is a pharmacy chain and health hub in East Africa.

The Debevoise team is led by M&A partner Geoffrey Burgess and includes associate Clarissa McNerney and tax associate Heather Atkins.